This company listing is no longer active
IM7 Stock Overview
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Inari Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$75.00 |
| 52 Week High | US$78.50 |
| 52 Week Low | US$34.20 |
| Beta | 1.03 |
| 1 Month Change | -1.96% |
| 3 Month Change | 59.57% |
| 1 Year Change | 41.51% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 34.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| IM7 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -2.0% | -0.3% | 1.1% |
| 1Y | 41.5% | -9.9% | 16.0% |
Return vs Industry: IM7 exceeded the German Medical Equipment industry which returned -3% over the past year.
Return vs Market: IM7 exceeded the German Market which returned 18.5% over the past year.
Price Volatility
| IM7 volatility | |
|---|---|
| IM7 Average Weekly Movement | 17.2% |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: IM7's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IM7's weekly volatility has increased from 11% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,300 | Drew Hykes | www.inarimedical.com |
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons.
Inari Medical, Inc. Fundamentals Summary
| IM7 fundamental statistics | |
|---|---|
| Market cap | €4.49b |
| Earnings (TTM) | -€75.23m |
| Revenue (TTM) | €549.97m |
Is IM7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IM7 income statement (TTM) | |
|---|---|
| Revenue | US$574.50m |
| Cost of Revenue | US$75.74m |
| Gross Profit | US$498.76m |
| Other Expenses | US$577.34m |
| Earnings | -US$78.58m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.34 |
| Gross Margin | 86.82% |
| Net Profit Margin | -13.68% |
| Debt/Equity Ratio | 0% |
How did IM7 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/18 20:35 |
| End of Day Share Price | 2025/02/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Inari Medical, Inc. is covered by 3 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nisala Weerasuriya | Berenberg |
| Kristen Stewart | CL King & Associates, Inc. |
| null null | Equisights |